Can I read Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF on EtoBox?

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF by B. Chauffert; L. Feuvret; F. Bonnetain; L. Taillandier; D. Frappaz; H. Taillia; R. Schott; J. Honnorat; M. Fabbro; I. Tennevet; F. Ghiringhelli; J.S. Guillamo; X. Durando; D. Castera; M. Frenay; C. Campello; C. Dalban; J. Skrzypski; O. Chinot is a scholarly article available to read on EtoBox.

What is Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF about?

## Background: Prognosis of unresectable glioblastoma (gb) remains poor, despite temozolomide (tmz)-based chemoradiation. activity of bevacizumab (bev) and irinotecan (iri) has been reported in recurrent disease. we evaluated bev and iri as neo-adjuvant and adjuvant treatment combined with tmz-based chemoradiation for unresectable gb. ## Patients and methods: Patients with unresectable gb, age 18-70, ik ≥50 were eligible. the experimental arm (bev/iri) consisted of neo-adjuvant intravenous bev, 10 mg/kg, and iri, 125 mg/m(2), every 2 weeks for four cycles before radiotherapy (rt) (60 gy), concomitant oral tmz, 75 mg/m(2)/day, and bev, 10 mg/kg every 2 weeks. adjuvant bev and iri were given every 2 weeks for 6 months. the control arm consisted of concomitant oral tmz, 75 mg/m(2)/day during rt, and 150-200 mg/m(2) for 5 days every 28 days for 6 months. the use of bev was allowed at progression in the control arm. ## Results: Patients (120) were included from april 2009 to january 2011. the working hypothesis was that treatment would increase the progression-free survival at 6 month (pfs-6) from 50% to 66%. the primary objective was not achieved, and only 30 out of 60 patients were al

Author

B. Chauffert; L. Feuvret; F. Bonnetain; L. Taillandier; D. Frappaz; H. Taillia; R. Schott; J. Honnorat; M. Fabbro; I. Tennevet; F. Ghiringhelli; J.S. Guillamo; X. Durando; D. Castera; M. Frenay; C. Campello; C. Dalban; J. Skrzypski; O. Chinot

Publisher

Elsevier BV

Published

2014

Language

EN